Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report:  January 2, 2019

(Date of earliest event reported)



(Exact name of registrant as specified in its charter)






(State or other jurisdiction

of incorporation)


File Number)

(I.R.S. Employer

Identification No.)




5751 Copley Drive, Suite B, San Diego, CA


(Address of principal executive offices)

(Zip Code)


(858) 966-3000

(Registrant’s telephone number, including area code)



(Former Name or Former Address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 2, 2019, Brandi L. Roberts resigned her position as Chief Financial Officer and Secretary of Reva Medical, Inc. (the “Company”), effective January 4, 2019, to pursue other opportunities.


On January 2, 2019, the Board of Directors of the Company appointed Leigh F. Elkolli, the Company’s current Senior Director of Finance and Corporate Controller, as Chief Financial Officer and Corporate Secretary, effective January 4, 2019.  Ms. Elkolli will succeed Ms. Roberts as the Company’s principal financial officer and principal accounting officer.


Ms. Elkolli, age 47, has served as the Company’s Senior Director of Finance and Corporate Controller since August 2017. Prior to her tenure with the Company, Ms. Elkolli served as Director of Finance of Avidity Biosciences LLC from October 2013 to August 2017. From June 2010 to October 2013, Ms. Elkolli served as Director of Finance and Controller of ImpediMed Inc.  Prior to that, Ms. Elkolli served in a variety of roles, most recently as an audit manager, at Ernst & Young, LLP from September 2003 until June 2010.  She is a certified public accountant with the State of California. Ms. Elkolli received an A.S. in Accounting from the Champlain College and a B.B.A. in Accounting from Western Connecticut State University.


There are no family relationships between Ms. Elkolli and any director, executive officer or person nominated or chosen to become a director. Ms. Elkolli does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.


The Company intends to enter into a new employment agreement with Ms. Elkolli reflecting her new position with the Company, the details of which will be disclosed once executed.


On January 3, 2019 PST, the Company issued a press release announcing the changes described above, which press release is attached hereto as Exhibit 99.1.



Item 9.01   Financial Statements and Exhibits.











Announcement entitled, “Leigh Elkolli Promoted to Chief Financial Officer”






Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.





REVA Medical, Inc.





Date:  January 3, 2019

/s/ Regina E. Groves


Regina E. Groves


Chief Executive Officer




Exhibit 99.1



Leigh Elkolli Promoted to Chief Financial Officer


Sydney, Australia and San Diego, California (Friday, 4 January 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the promotion of Leigh Elkolli to the position of Chief Financial Officer and Corporate Secretary, effective January 4, 2019.  She will replace Brandi Roberts, who served as REVA’s Chief Financial Officer and Corporate Secretary since August 2017 until her resignation effective January 4, 2019.  Ms. Elkolli joined REVA in August 2017 as Senior Director of Finance and Corporate Controller.


Ms. Elkolli has over 15 years of public accounting and finance experience in the life science industry. She joined REVA from Avidity Biosciences, a privately held biotechnology company, where she was Director of Finance. Ms. Elkolli started her career with Ernst & Young where she spent seven years in their assurance services practice serving public and private clients in the life science and technologies industries.


About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s products include the Fantom Encore and MOTIV bioresorbable vascular scaffolds for the treatment of coronary artery disease and below-the-knee peripheral artery disease, respectively. REVA is currently selling Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey. REVA is based in San Diego, California.


Fantom, Fantom Encore, MOTIV, and Tyrocore are trademarks of REVA Medical, Inc.


Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



United States




Investor & Media Enquiries:

Investor Enquiries:

Media Enquiries:


REVA Medical, Inc.

Perpetuity Capital Pty Ltd

Buchan Consulting


Leigh Elkolli

Kim Jacobs

Rebecca Wilson


Chief Financial Officer

+61 438 217 279

+61 3 9866 4722


+1 858-966-3018

Andrew Cohen

+61 408 333 452



David Schull




Russo Partners




+1 858-717-2310









HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111     •     +1 (858) 966-3000     •     +1 (858) 966-3099 (FAX)     •     www.revamedical.com

AUSTRALIAN OFFICE:  Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000     •     +61 2 9237 2800     

ARBN 146 505 777          REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability